In an interview during the recent J.P. Morgan 39th Healthcare Conference, Chapman said Natera aims to build on its 2020 accomplishments, which included processing a record 1 million tests, successfully launching Signatera, and surpassing growth goals set before COVID-19 for its Prospera™ donor-derived, cell-free DNA (cfDNA) transplant assessment test . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge